Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most common cause of death from cancer worldwide. 1 The incidence of HCC in the US is increasing because of the rise in the prevalence of hepatitis C virus infection. 
Iodine-131-based Devices
131 I was the first radionuclide to have significant use as an intraarterial therapy for HCC. [23] [24] [25] 131 I is a γ-emitter with a relatively long half-life of 8.04 days and a maximum energy of 0.364MeV, and achieves a mean tissue penetration of 0.4mm. 131 I is most frequently used by exchange with the iodine moiety of lipiodol, a preparation of iodized poppyseed oil (Lipiocis ® ). Arterially administered lipiodol leaks out of vascular spaces and localizes in the tumor cell membrane and intracellular compartment. 26 Non-radioactive iodine is administered before treatment to saturate thyroid uptake and prevent the uptake of circulating radioisotope into the thyroid gland. 131 I-lipiodol has been used for treatment of unresectable HCCs, in the adjuvant setting after surgical resection, and also prior to surgical resection or liver transplantation. Randomized controlled trials in the adjuvant setting have shown statistically significant decreases in recurrence rate and improvements in overall survival in patients receiving 131 I-lipiodol radioembolization after surgical resection. 27, 28 Pre-surgical administration has confirmed the ability of 131 I-lipiodol to produce partial and complete tumor necrosis of resected or explanted tumors. 29 Because it does not occlude arterial flow, 131 I-lipiodol radioembolization has also been used in patients with unresectable and 73,000 microspheres and can deliver up to 150Gy.
51-53
Technical Considerations A technetium-99m MAA study is then performed to calculate the percentage of radiation that would be shunted to the lungs (see Figure 1 ).
Contraindications and Recommendations
The use of 90 Y radioembolization is contraindicated in patients whose 
Note the intense localization of the MAA in the tumor nodules in this patient with multifocal hepatocellular carcinoma compared with the surrounding liver. This should correlate with the relatively greater deposition of the therapeutic microspheres within the tumors. Also note the small amount of activity that reached the lungs by way of atriovenous shunts through the tumors.

The arteriovenous shunting occurs in the tumors, and the patients at highest risk for exclusion due to lung shunt are those with large tumor volumes and those with hepatic venous tumor thrombus.
For their entire 108-patient cohort, a significant trend toward longer median survival was seen in the non-PVT group (467 days, 15.6 months) compared with the others (p=0.005). Interestingly, this trend was not maintained in the group of patients with cirrhosis (385 days, 12.8 months; p=0.10), but was maintained in patients without cirrhosis (p=0.02). The authors concluded that patients without cirrhosis and without PVT had the highest survival observed in the study (813 days, 27.1 months; p=0.02). The authors report one patient who underwent right hepatectomy 40 days following treatment; 11 of 34 patients were downstaged to RFA and eight of 34 patients were transplanted. In this group of patients the overall survival was 84, 54, and 27% at one, two, and three years, respectively.
Median survival for the entire 35-patient cohort was 800 days. 
